Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

Status:
Completed

Trial end date:
2003-09-01

Target enrollment:

Participant gender:

The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.

Phase 1

Takeda